drug · small molecule
crizotinib
Marketedupdated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and non-small cell lung carcinoma and 14 investigational indications.
indications
investigational
NSCLC
targets
EML4-ALKNPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)ALK tyrosine kinase receptorHepatocyte growth factor receptorMacrophage-stimulating protein receptor
all catalysts(0)
nothing on the calendar yet
Trials studying crizotinib
- phase2National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- phase3A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- —Safety and Efficacy of Xalkori ROS1
- phase4Crizotinib Continuation Clinical Study
- phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- phase3A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- phase3A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- phase3A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 12, 2027
272 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Nov 6, 2029compositionUS 82170573.2y
- Nov 6, 2029compositionUS 82170573.2y
- Nov 6, 2029compositionUS 82170573.2y
- Nov 6, 2029compositionUS 82170573.2y
- Nov 6, 2029compositionUS 82170573.2y
- Oct 8, 2029compositionUS 78586433.2y
- Oct 8, 2029compositionUS 78586433.2y
- Oct 8, 2029compositionUS 78586433.2y
- Oct 8, 2029compositionUS 78586433.2y
- Oct 8, 2029compositionUS 78586433.2y
- May 12, 2027method-of-use (U-3057)US 7825137272d
- May 12, 2027method-of-use (U-3058)US 7825137272d
- May 12, 2027method-of-use (U-3057)US 7825137272d
- May 12, 2027method-of-use (U-3403)US 7825137272d
- May 12, 2027method-of-use (U-3058)US 7825137272d
FDA exclusivities (4)
- Jul 14, 2029ODE-407Orphan Drug (7y)2.9y
- Jul 14, 2029ODE-407Orphan Drug (7y)2.9y
- Jan 14, 2028ODE-328Orphan Drug (7y)1.4y
- Jan 14, 2028ODE-328Orphan Drug (7y)1.4y
News(5)
- GSK lung cancer drug gets speedy approval following $10.6B dealThe clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.biopharma_dive · 20d ago
- GSK boosts cancer pipeline with $11B Nuvalent buyoutThe British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.biopharma_dive · 2mo ago
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 3mo ago
- OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.onclive · 3mo ago
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that